Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURVIVE HERoes
2024-516173-76-01Phase 3Authorised
- Sponsor
- University Hospital Ulm
- Start
- Dec 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in breast cancer comparing Trastuzumab deruxtecan arm with Standard-of-care arm (2 arms). Primary endpoint: ctDNA clearance rate (primary). Planned start Dec 2024; status: authorised.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-516173-76-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516173-76-01.